17. Haemophilius, Bordetella, Legionella Flashcards
Haemophilus species and what they cause
- H. influenzae
-respiratory tract infection
-meningitis
-bloodstream infection - H. ducreyi
-chancroid (a sexually transmitted infection) - H. aphrophilius (now A. aphrophilus)
-HACEK endocarditis
H.influenza and H.aphrophilus colonise the upper respiratory tract
Where is H.influenzae found
nasopharynx of healthy adults and children
-capsulated or non-capsulated
Encapsulated H.influenzae type b strains
- severe invasive disease
- especially in young children in countries that do not include Hib vaccine in the infant schedule
- hyposplenism/asplenism
- congenital or acquired immunological deficiencies
- e.g. depletion of CD4 T-cell in HIV, complement deficiency
- has a anti-phagocytic polysaccharide capsule: PRP (polyribosylribitol phosphate) that:
a) makes it resistant to phagocytosis by PMN leukocytes in the absence of specific anti-capsular antibody
b) reduce the organism’s susceptibility to the bactericidal effect of serum
Non-encapsulated H.influenza
mainly associated with respiratory/mucosal infection
- acute exarcebation of chronic bronchitis
- otitis media, sinusitis, pneumonia
- may cause invasive disease
Capsulated H.influenza
divided into different strains using antisera against specific capsular polysaccharides
- 6 type: a-f
- b: Hib - most commonly associated with systemic disease
Virulence factors of capsulated H.influenzae
- capsule
- pili/fimbrae
- outer membrane proteins - adhesion proteins
- lipooligosaccharide
- antimicrobial resistance
Pathogenesis of infection with capsulated H.influenzae
- inhalation of respiratory droplets or direct contact with respiratory secretions
- colonization of oropharynx
- fimbriae/pili attachments to respiratory epithelial cells
- capsule is the critical virulence factor that facilitates invasion and haematogenous dissemination
- capsular and lack of anti-PRP antibody complement activation of endotoxin acting on the lipopolysaccharide
Virulence factors of non-capsulated H. influenzae and their biological role
- fimbrae - attachment to pharyngeal cells
- opacity-associated protein (Aap) - attachment to pharyngeal cell
- IgA protease - inactivate IgA in the nasopharynx
- lipooligosaccharide - endotoxin activity when the organism are lysed
- antimicrobial resistance (esp. beta-lactamase protein)
Pathogenesis of infection with non-capsulated H.influenzae
- commonly colonise patients with chronic pulmonary disease (e.g. COPD, cystic fibrosis)
- ciliated columnar epithelium is damaged by air pollutants, smoking
- damaged cilia or reduction in the number of ciliated cells allow collection/pooling of mucus
- biofilm formation
- predisposes to invasion by bacteria
- preceding or coincident viral infection may also precipitate infection
H. influenzae type B may cause
- respiratory tract infections in early childhood
- acute epiglottis
- pneumonia - meningitis
- untreated -> very high mortality
- deafness, seizures and intellectual impairment - septicaemia
- septic arthritis
- cellulitis (closed, spreading)
Non-capsulated H. influenzae may cause
- recurrent sinusitis
- acute/chronic bronchitis
- acute and chronic otitis media
- community-acquired pneumonia
- invasive infection (less common)
Laboratory features of haemophilus species
- pleomorphic gram negative bacilli/coccobacilli
- stain faintly
- facultatively anaerobic
- max growth in 5% CO2 - fastidious
- require either X factor (haemin) or V factor (NAD) or both
- both found in chocolate agar
- H.influenzae require both
Laboratory diagnosis of systemic infections such as epiglottis, bloodstream infection, cellulitis and septic arthritis
- blood culture
- joint fluid (septic arthritis)
- aspirate from area of cellulitis
- swab for culture and antibiotic susceptibility
Laboratory diagnosis of suspected meningitis
- blood culture and PCR
2. CSF for microscopy, culture and PCR
Antibiotic treatment for haemophilus species
- naturally resistant to penicillin
- beta-lactamase producers
- resistant to amoxicillin
1. In-patient treatment - IV co-amoxiclav (respiratory infection)
- IV cefotaxime/ceftriaxone (BSI, meningitis)
2. Out-patient treatment - oral co-amoxilav
- macrolide (e.g. clarithromycin)